Key Highlights

  • TELA Bio appointed Heather Getz as Chief Executive Officer and Director, effective immediately, succeeding company co-founder Tony Koblish.
  • Getz most recently served as Executive Vice President and Chief Financial and Operations Officer at Butterfly Network.
  • During her prior role at BioTelemetry, Getz oversaw growth in the company's market capitalization from 50 million dollars to 2.8 billion dollars before its acquisition by Philips Healthcare in 2021.
  • Koblish, who founded TELA Bio and led development of its OviTex soft tissue reconstruction product, is departing the company after leading its growth and commercialization efforts.

A Leadership Transition at a Commercial-Stage Medical Technology Company

TELA Bio (NASDAQ:TELA), a commercial-stage medical technology company focused on soft tissue reconstruction solutions, announced that its board of directors has appointed Heather Getz as Chief Executive Officer and Director, effective immediately. Getz succeeds company co-founder Tony Koblish, whose entrepreneurial leadership the board credited with establishing TELA Bio as a leader in soft tissue reconstruction through the development of its OviTex product line.

The company's board chairman said Getz brings a proven track record of driving operational excellence and leading organizations through complex business and financial transformations, framing her appointment as positioning TELA Bio for its next phase of growth and commercial execution. The board separately expressed gratitude to Koblish for his vision and entrepreneurial spirit in founding the company, acknowledging his contributions to establishing TELA Bio's market position ahead of this leadership transition.

A Background in Financial Leadership Across Medical Technology Companies

Getz joins TELA Bio from Butterfly Network, where she served as Executive Vice President and Chief Financial and Operations Officer, a role in which she is credited with implementing transformative changes to the company's strategy, capital allocation, cash runway management and investor relations while building a performance-oriented culture. Prior to Butterfly Network (NYSE:BFLY), Getz held the position of Executive Vice President and Chief Financial and Administrative Officer at BioTelemetry, a remote medical technology company.

During her tenure at BioTelemetry, the company's market capitalization grew from 50 million dollars to 2.8 billion dollars prior to its acquisition by Philips Healthcare in 2021, a scale of value creation that represents a substantial track record heading into her new role leading TELA Bio. Getz has also held executive positions at Healthy.io, VIASYS Healthcare and Alita Pharmaceuticals, rounding out a career concentrated specifically within medical technology and healthcare-adjacent companies.

Financial Background Suggests a Focus on Operational and Capital Discipline

Getz's professional background is weighted heavily toward financial and operational leadership roles rather than clinical or research-focused positions, a profile that may signal a strategic emphasis on capital efficiency, commercial execution and financial discipline as TELA Bio moves into its next growth phase. This type of leadership transition, from a founder with deep product and technical vision to an executive with a demonstrated financial transformation track record, often reflects a company's evolution from an early commercialization stage toward a phase requiring more disciplined operational scaling.

Given her direct experience overseeing substantial market capitalization growth at BioTelemetry through to a successful acquisition outcome, Getz's appointment could signal the board's interest in strengthening TELA Bio's financial positioning and investor relations as the company continues its commercial execution efforts. Whether this leadership profile translates into a similar trajectory of value creation at TELA Bio will depend on execution across a business that, unlike BioTelemetry at the time of her tenure there, is still navigating an earlier stage of commercial scaling within a specialized surgical technology niche.

Conclusion

TELA Bio's appointment of Heather Getz introduces a leader with an extensive financial and operational track record across medical technology companies, transitioning leadership away from the company's founding entrepreneur toward an executive with demonstrated experience scaling companies through significant growth and eventual acquisition outcomes. The board's stated confidence in Getz's ability to build on TELA Bio's existing commercial foundation suggests an emphasis on accelerating execution rather than a fundamental strategic pivot. How effectively Getz translates her prior financial transformation experience into TELA Bio's specific commercial and clinical context is likely to become clearer as the company reports results under her leadership in coming quarters.